

Toshio Imai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4321505/publications.pdf>

Version: 2024-02-01

26
papers

3,945
citations

430442

18
h-index

552369

26
g-index

26
all docs

26
docs citations

26
times ranked

4201
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification and Molecular Characterization of Fractalkine Receptor CX3CR1, which Mediates Both Leukocyte Migration and Adhesion. <i>Cell</i> , 1997, 91, 521-530.	13.5	1,272
2	Fractalkine and CX3CR1 Mediate a Novel Mechanism of Leukocyte Capture, Firm Adhesion, and Activation under Physiologic Flow. <i>Journal of Experimental Medicine</i> , 1998, 188, 1413-1419.	4.2	641
3	Chemokines in Immunity. <i>Advances in Immunology</i> , 2001, 78, 57-110.	1.1	392
4	Dual Functions of Fractalkine/CX3C Ligand 1 in Trafficking of Perforin+/Granzyme B+ Cytotoxic Effector Lymphocytes That Are Defined by CX3CR1 Expression. <i>Journal of Immunology</i> , 2002, 168, 6173-6180.	0.4	308
5	CX3C-Chemokine, Fractalkine-Enhanced Adhesion of THP-1 Cells to Endothelial Cells Through Integrin-Dependent and -Independent Mechanisms. <i>Journal of Immunology</i> , 2000, 164, 4313-4320.	0.4	199
6	Inhibition of Fractalkine Ameliorates Murine Collagen-Induced Arthritis. <i>Journal of Immunology</i> , 2004, 173, 7010-7016.	0.4	136
7	Migration of CX3CR1-positive T cells producing type 1 cytokines and cytotoxic molecules into the synovium of patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2002, 46, 2878-2883.	6.7	128
8	Role of CX3CL1/Fractalkine in Osteoclast Differentiation and Bone Resorption. <i>Journal of Immunology</i> , 2009, 183, 7825-7831.	0.4	125
9	Fractalkine and vascular injury. <i>Trends in Immunology</i> , 2001, 22, 602-607.	2.9	123
10	Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice. <i>Arthritis and Rheumatism</i> , 2005, 52, 1522-1533.	6.7	117
11	Fractalkine, a CX3C chemokine, functions predominantly as an adhesion molecule in monocytic cell line THP-1. <i>Immunology and Cell Biology</i> , 2001, 79, 298-302.	1.0	86
12	T cell costimulation by fractalkine-expressing synoviocytes in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2005, 52, 1392-1401.	6.7	85
13	Roles of chemokine receptor CX3CR1 in maintaining murine bone homeostasis through the regulation of both osteoblasts and osteoclasts. <i>Journal of Cell Science</i> , 2013, 126, 1032-45.	1.2	59
14	Safety, pharmacokinetics, and efficacy of E6011, an anti-fractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis. <i>Modern Rheumatology</i> , 2018, 28, 58-65.	0.9	54
15	Inhibition of CX3CL1 (Fractalkine) Improves Experimental Autoimmune Myositis in SJL/J Mice. <i>Journal of Immunology</i> , 2005, 175, 6987-6996.	0.4	53
16	Therapeutic intervention of inflammatory/immune diseases by inhibition of the fractalkine (CX3CL1)-CX3CR1 pathway. <i>Inflammation and Regeneration</i> , 2016, 36, 9.	1.5	37
17	Role of Anti-Fractalkine Antibody in Suppression of Joint Destruction by Inhibiting Migration of Osteoclast Precursors to the Synovium in Experimental Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 222-231.	2.9	28
18	Serum level of soluble CX3CL1/fractalkine is elevated in patients with polymyositis and dermatomyositis, which is correlated with disease activity. <i>Arthritis Research and Therapy</i> , 2012, 14, R48.	1.6	25

#	ARTICLE	IF	CITATIONS
19	Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 587-595.	2.9	17
20	<p><p>Emerging Role of Fractalkine in the Treatment of Rheumatic Diseases</p>. <i>ImmunoTargets and Therapy</i> , 2020, Volume 9, 241-253.	2.7	15
21	Anti-Apoptotic Effects of Recombinant Human Hepatocyte Growth Factor on Hepatocytes Were Associated with Intrahepatic Hemorrhage Suppression Indicated by the Preservation of Prothrombin Time. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1821.	1.8	12
22	Inhibition of the Progression of Skin Inflammation, Fibrosis, and Vascular Injury by Blockade of the CX ₃ CL ₁ /CX ₃ CR ₁ Pathway in Experimental Mouse Models of Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1923-1934.	2.9	11
23	A phase 2 study of E6011, an anti-Fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs. <i>Modern Rheumatology</i> , 2021, 31, 783-789.	0.9	11
24	Treatment with an Anti-CX ₃ CL ₁ Antibody Suppresses M1 Macrophage Infiltration in Interstitial Lung Disease in SKG Mice. <i>Pharmaceuticals</i> , 2021, 14, 474.	1.7	5
25	Monoclonal antibodies specific for podocalyxin expressed on human induced pluripotent stem cells. <i>Biochemical and Biophysical Research Communications</i> , 2020, 532, 647-654.	1.0	3
26	Serum APOA4 Pharmacodynamically Represents Administered Recombinant Human Hepatocyte Growth Factor (E3112). <i>International Journal of Molecular Sciences</i> , 2021, 22, 4578.	1.8	3